|Two for your watchlist|
|By Vinny Cassano|
|Wednesday, 27 April 2011 08:32|
Stimuvax is a cancer immunotherapy treatment, like Dendreon's Provenge, that is currently being developed with commercial partner Merck KGaA for the treatment of non-small cell lung cancer.
While ONTY also has multiple PI-3 Kinase Inhibitors in Phase II trials, the Phase III Stimuvax is the closest product to market and provides the best short term potential to bear market-moving news.
The monumental rise of Dendreon following the approval of Provenge for the treatment of prostate cancer last year makes all investments in the cancer vaccine sector an appetizing pick, and Stimuvax is one of the later-staged candidates of those being developed.
The latest run could be related to the pending release of Stimuvax results, whether interim or additional long term follow-up, as there are some high profile cancer treatment conferences upcoming; but it's worth keeping this one on the radar, regardless.
One cause for the increased interest could be the Novartis earnings report from earlier this week that showed a sharp increase in Fanapt sales.
Titan receives an 8% royalty on Fanapt sales, and the quarter one number was nine million dollars. That would make Titan's cut just over $700,000.
These volume/price moves are not uncommon for TTNP, and are often followed by sharp moves, whether it be to the upside or downside.
Since the stock has been trading at the lower end of the range set up this year, it's possible that the boost in volume could be tipping off another move up.
Probuphine results are also just around the corner, so Titan should be all over the biotech watch lists right now, in my opinion.
Keep in mind this stock's history of quick retreats after price surges, but then again - the company has never been on as solid footing as it is right now, at least in terms of pipeline developments.
Stay glued to Titan, this one might be getting warmed up.
Disclosure: Long TTNP, ONTY.
Vinny authors the popular stock investing blog, VFC's Stock House.